Technology area: Biotechnology & Pharmaceuticals
84 pending office actions • 56 art units • 82 examiners • 0 of 84 (0%) have an AI response strategy ready • 78 patents granted in the last 365 days
Duke University has 86 pending office actions in Biotechnology & Pharmaceuticals, involving 84 examiners across 58 art units. REDDIG, PETER J is the busiest named examiner, with 2 pending matters.
The figures show a broad and highly dispersed prosecution portfolio. The pending matters are not centered on a small examiner group, so docket administration, art-unit tracking, and application-specific issue analysis are central practical concerns.
Because the technology area spans biotechnology and pharmaceuticals, claim strategy may vary substantially between matters. Portfolio counsel can benefit from a structured system for identifying recurring disclosure positions, coordinating related filings, and distinguishing examiner-specific requirements without assuming uniform treatment.
Based on the USPTO statutory response window for each pending office action. 22 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 22 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 17 (20%) |
| §103 only | 19 (23%) |
| §102 only | 2 (2%) |
| §112 only | 6 (7%) |
| Double-patenting only | 1 (1%) |
| Double-patenting + other | 10 (12%) |
| Multi-statute (no §101) | 29 (35%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 2 | 58.0% | +40.2% |
| GRABER, JAMES J | 2 | 46.5% | +57.6% |
| ALBERS, KEVIN S | 1 | 25.4% | +50.4% |
| STRACHAN, KATE ELIZABETH | 1 | 49.6% | +31.5% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
| MI, QIUWEN | 1 | 68.4% | +50.0% |
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| CARLSON, JOSHUA MICHAEL | 1 | 60.0% | +38.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18925601 | METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE | ROCHELLE, CIERRA MARIE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919997 | COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES | SIFFORD, JEFFREY MARK | 2d overdue |
| 18962035 | NON-INVASIVE ORTHOSIS FOR IMMOBILIZING THE CERVICAL SPINE | ALBERS, KEVIN S | 14d |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | GRABER, JAMES J | 15d |
| 18007879 | COMPOSITIONS AND METHODS FOR AUGMENTING AUTOLOGOUS FAT GRAFTS | BEANE, RANDALL L | 20d |
| 18024091 | METHODS FOR REPROGRAMMING TARGET CELLS | CORDAS, EMILY ANN | 27d |
| 18867588 | SYSTEMS AND METHODS FOR CALCULATING VOLUMES OF EXCRETED URINE AND STOOL | STRACHAN, KATE ELIZABETH | — |
| 18862323 | PATIENT-DERIVED CELL-CONTAINING DROPLETS ENABLE CLINICAL PRECISION ONCOLOGY | THUESON, HANNA MARIE | — |
| 18893942 | KNEE IMPLANT | JANOSKO, CHASITY PAIGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18962035 | NON-INVASIVE ORTHOSIS FOR IMMOBILIZING THE CERVICAL SPINE | ALBERS, KEVIN S | 14d |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | GRABER, JAMES J | 15d |
| 18867588 | SYSTEMS AND METHODS FOR CALCULATING VOLUMES OF EXCRETED URINE AND STOOL | STRACHAN, KATE ELIZABETH | — |
| 18862323 | PATIENT-DERIVED CELL-CONTAINING DROPLETS ENABLE CLINICAL PRECISION ONCOLOGY | THUESON, HANNA MARIE | — |
| 18927395 | MODULAR BIOMATERIAL PLATFORM LOCAL, INJECTABLE DELIVERY OF A DRUG AND METHODS OF MAKING AND USING SAME | MI, QIUWEN | — |
| 18893942 | KNEE IMPLANT | JANOSKO, CHASITY PAIGE | — |
| 18824144 | INTRAOPERATIVE ON-SPOT ABNORMAL TISSUE DETECTION | CARLSON, JOSHUA MICHAEL | — |
| 18511817 | CHIMERIC APOPTOTIC SIGNAL TARGETING LYMPHOCYTES (TIM-4 CASTL) AND METHODS OF MAKING AND USING SAME | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1632 | 5 |
| 1638 | 3 |
| 1656 | 3 |
| 1671 | 3 |
| 1675 | 3 |
| 1636 | 3 |
| 1672 | 3 |
| 1637 | 3 |
| 1627 | 2 |
| 1624 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18962035 | NON-INVASIVE ORTHOSIS FOR IMMOBILIZING THE CERVICAL SPINE | ALBERS, KEVIN S | 3786 | §103 | Final Rejection | 14d | Pending | Nov 27, 2024 |
| 18867588 | SYSTEMS AND METHODS FOR CALCULATING VOLUMES OF EXCRETED URINE AND STOOL | STRACHAN, KATE ELIZABETH | 3781 | §102§103 | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18862323 | PATIENT-DERIVED CELL-CONTAINING DROPLETS ENABLE CLINICAL PRECISION ONCOLOGY | THUESON, HANNA MARIE | 1638 | §103§112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18927395 | MODULAR BIOMATERIAL PLATFORM LOCAL, INJECTABLE DELIVERY OF A DRUG AND METHODS OF MAKING AND USING SAME | MI, QIUWEN | — | §112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18925601 | METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE | ROCHELLE, CIERRA MARIE | 1627 | §103§112DP | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18893942 | KNEE IMPLANT | JANOSKO, CHASITY PAIGE | 1613 | §103§112 | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18849279 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | JACKSON, SHAWQUIA | 1626 | §102§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18824144 | INTRAOPERATIVE ON-SPOT ABNORMAL TISSUE DETECTION | CARLSON, JOSHUA MICHAEL | 2877 | §103 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18759522 | RISK DETECTION WITH ACTIONABLE GUIDANCE FOR NEURODEVELOPMENTAL DISORDERS | AKOGYERAM II, NICHOLAS A | 3686 | §101§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18680164 | DEVICES AND METHODS FOR CREATING TRANSCELLULAR PORES | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18713948 | METALLIC SINGLE-WALLED CARBON NANOTUBE HYBRID ASSEMBLIES AND SUPERSTRUCTURES | THOMPSON, CAMIE S | 1786 | §103 | Non-Final OA | — | Pending | May 28, 2024 |
| 18668784 | METHOD AND SYSTEM FOR NOISE CANCELLATION BASED ON QUBIT FEEDBACK | EBERSMAN, BRUCE I | 3693 | §103 | Non-Final OA | — | Pending | May 20, 2024 |
| 18707971 | Compositions and Methods for Modulating the Effect of Beta-Blocker Activity in a Subject | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18649219 | MACHINE LEARNING AIDED REALISM-ENHANCED VIRTUAL CLINICAL IMAGING WITH GROUND TRUTH PRESERVATION | TRAN, JENNY NGAN | 2615 | §101§103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18703125 | COMPOSITIONS AND METHODS FOR TARGETING GPCR FOR THE PREVENTION AND TREATMENT OF PAIN | GONZALEZ, LUISALBERTO | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18639337 | FUNCTIONAL OUTCOMES AFTER SPINAL CORD INJURY | MATTHEWS, JOSEPH RICCI | 1656 | §102§103 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18700677 | COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES | FOLEY, SHANON A | 1671 | §101§102§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18629315 | SYSTEMS AND METHODS FOR SEEDLESS FRUIT TRAIT | CHATTERJEE, JAYANTA | 1662 | §102§112 | Final Rejection | — | Pending | Apr 08, 2024 |
| 18629894 | LASOFOXIFENE TREATMENT OF BREAST CANCER | PECKHAM, RICHARD GRANT | 1627 | §101§103§112 | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18626187 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CHENG, KAREN | 1623 | §102§103 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18697976 | COMPOSITIONS COMPRISING SMALL MOLECULE REGULATORS OF TUMOR IMMUNITY AND METHODS OF USING SAME | WILSON, JERICA KATLYNN | 1621 | §103§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18611203 | Systems and Methods for the Direct Comparison of Molecular Derivatives | ACOSTA, RILEY SULLIVAN | 2143 | §101§102§103 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18581157 | COMPUTATIONAL IMAGE CONTRAST FROM MULTI-DIMENSIONAL DATA | BUDISALICH, ANDREW STEVEN | 2662 | §103 | Final Rejection | — | Pending | Feb 19, 2024 |
| 18684346 | NEXT GENERATION VACCINES COMPRISING ANTIGENIC LIBRARIES AND METHODS OF MAKING AND USING SAME | GILL, RACHEL B | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18683650 | NON-IMMUNOGENIC, HIGH DENSITY POEGMA CONJUGATES | CESARE, JOSEPH DAVID | 1675 | §102§103 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18578262 | VOLUME REDUCTION SOLIDS TREATMENT SYSTEM | GURTOWSKI, RICHARD C | 1773 | §103 | Non-Final OA | 49d | Pending | Jan 10, 2024 |
| 18575098 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | MOSHER, ERIC PARKER | 1612 | §102§103§112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18392091 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING PATHOLOGICAL FIBROBLAST CELLS | MELCHIOR, JAMES RYLAND | 1644 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18545176 | Combination Treatment | KELLY, ROBERT M | — | §112Other | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18570967 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEMOGLOBINOPATHIES | YU, DELPHINUS DOU YI | 1636 | §103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18532709 | COMPLEMENT FACTOR H ANTIBODIES | SZPERKA, MICHAEL EDWARD | 1641 | §101§102§112DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18513095 | TARGETED INHIBITION OF DKK3 TO SENSITIZE TUMORS TO IMMUNOTHERAPY | STOICA, ELLY GERALD | 1647 | §102§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18511825 | RECOMBINANT TIM-4 PROTEIN, CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL DELIVERY SYSTEM AND METHODS OF MAKING AND USING SAME | BORGEEST, CHRISTINA M | 1675 | §103 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18511817 | CHIMERIC APOPTOTIC SIGNAL TARGETING LYMPHOCYTES (TIM-4 CASTL) AND METHODS OF MAKING AND USING SAME | REDDIG, PETER J | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18510007 | COMPOSITIONS AND METHODS FOR HIGH STRINGENCY ISOLATION OF NUCLEIC ACIDS | CREWS, JARET JAMES | 1691 | §102§103 | Final Rejection | — | Pending | Nov 15, 2023 |
| 18499880 | METHODS FOR DETECTING ONCOGENIC KRAS MUTATIONS | BELLAH, JEFFREY LAWRENCE | 1683 | §103§112 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18557787 | ENGINEERED INFLUENZA VIRUSES EXPRESSING SARS-COV-2 ANTIGENS, VACCINES AND METHODS OF MAKING AND USING THE SAME | JADHAO, SAMADHAN JAISING | 1672 | §101§103 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18288505 | COMPOSITIONS AND METHODS FOR RAPID GENERATION OF MODIFIABLE STABLE CELL LINES | BEHARRY, ZANNA MARIA | 1632 | §103§112DP | Final Rejection | 63d | Pending | Oct 26, 2023 |
| 18556393 | TWO-STAGE DYNAMIC CONTROL OVER REDOX STATE IMPROVES CYSTOLIC EXPRESSION OF DISULFIDE CONTAINING PROETEINS IN E. COLI | HOLLAND, PAUL J | 1656 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18486146 | M6A-COUPLED EFFECTOR PROTEIN EXPRESSION SYSTEM AND METHODS OF MAKING AND USING SAME | ALLEN, SARAH ELIZABETH | 1637 | §101§112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18553703 | METHODS FOR DETERMINING TUMOR IMMUNE STATUS | NICKOL, GARY B | 1643 | §101§103 | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18552693 | Compositions For and Methods of Editing the Genome | MONTANARI, DAVID A | 1632 | §102 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18474697 | SYSTEMS AND METHODS FOR EXOSOME DELIVERY OF MICRORNAS FOR CELLULAR REPROGRAMMING | SMALL, KATHERINE R | 1633 | §101§102§103§112 | Final Rejection | — | Pending | Sep 26, 2023 |
| 18551547 | COMPOSITIONS AND METHODS FOR RAPID COVID-19 DETECTION | CHEN, STACY BROWN | 1672 | §102§103§112 | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18550928 | GENERATION OF NOVEL CRISPR GENOME EDITING AGENTS USING COMBINATORIAL CHEMISTRY | OLSON, ALEXANDRA NADINE | 1684 | §102§103§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18547332 | Compositions For and Methods of Improving Gene Therapy | GRABER, JAMES J | 1631 | §102§103 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18271983 | COMPOSITIONS AND METHODS FOR THE GENETIC MANIPULATION OF THE INFLUENZA VIRUS | GRIZER, CASSANDRA SENN | 1672 | §103 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18036862 | TARGETED GENE REGULATION OF HUMAN IMMUNE CELLS WITH CRISPR-CAS SYSTEMS | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18312719 | SYSTEMS AND METHODS FOR PROMOTING REMYELINATION WITH FACTORS DERIVED FROM UMBILICAL CORD BLOOD MACROPHAGES | DENT, ALANA HARRIS | 1643 | §102§103DP | Final Rejection | 20d | Pending | May 05, 2023 |
| 18033049 | DUAL AAV VECTOR-MEDIATED DELETION OF LARGE MUTATIONAL HOTSPOT FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ARIETI, RUTH SOPHIA | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDuke University has 84 pending office actions as of October 2026, spread across 56 art units and 82 examiners.
Peter J Reddig has the most, with 2 of Duke University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
